新たな抗体製品を利用した治療法の開発

1日目  |  2日目 

10月12日水曜日

13:00 Conference Registration

 

Novel Fragments And Peptides
(新たなフラグメントとペプチド)

14:00 Chairperson’s Remarks

KEYNOTE PRESENTATION 14:05 From Bench to Clinic: Experiences with Cytokine-Antibody Fusion Proteins Dario Neri, Ph.D., Professor, Chemistry and Applied Biosciences, ETH Zurich - Biography Antibodies can be used to deliver cytokines to sites of disease (e.g., to the tumor environment), thus enabling therapeutic interventions which spare normal tissues. The antibody-based targeting of tumor neo-vasculature is particularly attractive, because of the dependence of cancer on new blood vessels and because of the accessibility of these structures from the blood-stream. Pre-clinical and clinical results obtained with vascular targeting immunocytokines will be presented in this lecture.

14:35 Development of a Novel anti-CD37 Single-Chain Mono-Specific Polypeptide Drug for the Treatment of B-Cell Malignancies

Paul Algate, Ph.D., Director, Non-Clinical Research, Emergent Biosolutions - Biography

TRU-016 is a novel humanized anti-CD37 small modular immunopharmaceutical (SMIPTM) molecule that mediates direct and indirect killing of normal and malignant B-cells. Pre-clinical data will be presented demonstrating mechanisms of action and combinatorial activity with other therapeutics. The status of clinical studies investigating the therapeutic potential of TRU-016 against B-cell malignancies will be discussed.

15:05 Pre-Clinical Development of Fc-Domain Optimized Monoclonal Antibodies with Increased Anti-Tumor Activity

Ezio Bonvini, M.D., Senior Vice President, Research, Macrogenics, Inc. - Biography

There is strong rationale for engineering the Fc domain of monoclonal antibodies to enhance Fc-dependent effector functions. Pre-clinical validation of Fc-optimized antibodies, however, presents challenges in efficacy evaluation, safety assessment and pharmacology. This case study will address potential solutions from our experience in the development of two Fc-optimized monoclonal antibodies for cancer treatment, including engineering, in vitro characterization, in vivo tumor modelling and pre-clinical toxicology in non-human primates.

15:35 Refreshment Break - Networking with Sponsors

 

Antibody Drug Conjugates
(抗体医薬品複合体)

16:15 Sponsored Presentation (Opportunity Available)


16:45 Calicheamicin Antibody-Drug Conjugates and Beyond

Puja Sapra, Ph.D., Director, Bioconjugates, Oncology Research, Pfizer, Inc. - Biography

CMC-544 (inotuzumab ozogamicin), an anti-CD22-calicheamicin conjugate, is currently being evaluated in B-cell non-Hodgkin’s lymphoma (B-NHL) patients. This presentation will provide the mechanism of action of calicheamicin immunoconjugates with focus on pre-clinical and clinical data on CMC-544. Further, pre-clinical data for a novel antibody-drug conjugate (ADC) targeting cancer stem cells will be discussed. Challenges in ADC development and potential strategies to overcome these challenges will be reviewed.

17:15 Advances in Linker and Payload Technology

Ravi Chari, Ph.D., Executive Director, Chemistry & Biochemistry, Immunogen, Inc. - Biography

Multiple antibody-drug conjugates (ADCs) made with ImmunoGen’s maytansinoid cell killing agents are undergoing clinical evaluation. ImmunoGen has developed approaches to tailor each maytansinoid conjugate to achieve the best performance for the specific cancer target. Incorporation of new polar linkers has resulted in antibody-maytansinoid conjugates with enhanced potency towards multidrug resistant tumors in pre-clinical models. The presentation will highlight advances in linker design and new effector molecules for ADCs.

PLENARY KEYNOTE SESSION (基調セッション) 18:00 Keynote Introduction 18:05 Protein Engineering: Benefiting Therapeutic Proteins and Small Molecule Drugs Alike Andreas Plueckthun, Ph.D., Professor, Biochemical Institute, University of Zurich     18:40 Keynote Presentation

19:15 – 21:00 CHI Networking Dinner Reception